 Connection
Frank Scott to Crohn Disease
This is a "connection" page, showing publications Frank Scott has written about Crohn Disease.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
4.516 |
|
|
|
-
Constant BD, de Zoeten EF, Weinman JP, Albenberg L, Scott FI. Early Anti-Tumor-Necrosis-Factor Therapy for Crohn's Disease-Related Abdominal Abscesses and Phlegmon in Children. Dig Dis Sci. 2023 03; 68(3):877-888.
Score: 0.655
-
Haydek JP, Scott FI. Editorial: infliximab or adalimumab as first- or second-line anti-TNF-conflicting evidence. Aliment Pharmacol Ther. 2021 09; 54(6):846-847.
Score: 0.618
-
Scott FI, Hans AK, Gerich ME, Fennimore B, Mamtani R, Vajravelu RK, Lewis JD. Identification of the Most Effective Position for Ustekinumab in Treatment Algorithms for Crohn's Disease. Clin Gastroenterol Hepatol. 2021 10; 19(10):2082-2092.e10.
Score: 0.574
-
Scott FI, Johnson FR, Bewtra M, Brensinger CM, Roy JA, Reed SD, Osterman MT, Mamtani R, Chen L, Yun H, Xie F, Curtis JR, Lewis JD. Improved Quality of Life With Anti-TNF Therapy Compared With Continued Corticosteroid Utilization in Crohn's Disease. Inflamm Bowel Dis. 2019 04 11; 25(5):925-936.
Score: 0.523
-
Scott FI, Lichtenstein GR. Approach to the Patient with Mild Crohn's Disease: a 2016 Update. Curr Gastroenterol Rep. 2016 Sep; 18(9):50.
Score: 0.437
-
Scott FI, Osterman MT. Natalizumab for Crohn's Disease: Down but Not Out. Clin Gastroenterol Hepatol. 2015 Nov; 13(11):1926-8.
Score: 0.404
-
Scott FI, Vajravelu RK, Bewtra M, Mamtani R, Lee D, Goldberg DS, Lewis JD. The benefit-to-risk balance of combining infliximab with azathioprine varies with age: a markov model. Clin Gastroenterol Hepatol. 2015 Feb; 13(2):302-309.e11.
Score: 0.379
-
Scott FI, Osterman MT, McConnell RA, Lorusso M, Aberra F, Kerner C, Lichtenstein GR, Lewis JD. Impact of JC virus antibody testing in patients with Crohn's disease with loss of response to infliximab: a Markov model. Inflamm Bowel Dis. 2013 Nov; 19(12):2625-33.
Score: 0.359
-
Singh S, Proctor D, Scott FI, Falck-Ytter Y, Feuerstein JD. AGA Technical Review on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease. Gastroenterology. 2021 06; 160(7):2512-2556.e9.
Score: 0.152
-
Lefferts AR, Regner EH, Stahly A, O'Rourke B, Gerich ME, Fennimore BP, Scott FI, Freeman AE, Jones K, Kuhn KA. Circulating mature granzyme B+ T cells distinguish Crohn's disease-associated axial spondyloarthritis from axial spondyloarthritis and Crohn's disease. Arthritis Res Ther. 2021 05 22; 23(1):147.
Score: 0.151
-
Bewtra M, Reed SD, Johnson FR, Scott FI, Gilroy E, Sandler RS, Chen W, Lewis JD. Variation Among Patients With Crohn's Disease in Benefit vs Risk Preferences and Remission Time Equivalents. Clin Gastroenterol Hepatol. 2020 02; 18(2):406-414.e7.
Score: 0.132
-
Henao MP, Bewtra M, Osterman MT, Aberra FN, Scott FI, Lichtenstein GR, Kraschnewski J, Lewis JD. Measurement of Inflammatory Bowel Disease Symptoms: Reliability of an Abbreviated Approach to Data Collection. Inflamm Bowel Dis. 2015 Oct; 21(10):2262-71.
Score: 0.102
-
Lewis JD, Scott FI, Brensinger CM, Roy JA, Osterman MT, Mamtani R, Bewtra M, Chen L, Yun H, Xie F, Curtis JR. Increased Mortality Rates With Prolonged Corticosteroid Therapy When Compared With Antitumor Necrosis Factor-a-Directed Therapy for Inflammatory Bowel Disease. Am J Gastroenterol. 2018 03; 113(3):405-417.
Score: 0.030
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|